Statins and intracerebral hemorrhage: Collaborative systematic review and meta-analysis

Circulation

Volumn 124, Issue 20, 2011, Pages 2233-2242

  Hackam, Daniel G ^a   Woodward, Mark ^b   Newby, L Kristin ^c   Bhatt, Deepak L ^d   Shao, Mingyuan ^e   Smith, Eric E ^f   Donner, Allan ^a   Mamdani, Muhammad ^g   Douketis, James D ^h   Arima, Hisatomi ^b   Chalmers, John ^b   MacMahon, Stephen ^b   Tirschwell, David L ⁱ   Psaty, Bruce M ⁱ   Bushnell, Cheryl D ^j   Aguilar, Maria I ^k   Capampangan, Dan J ^k   Werring, David J ^l   De Rango, Paola ^m   Viswanathan, Anand ⁿ   Danchin, Nicolas ^o   Cheng, Ching Lan ^p   Yang, Yea Huei Kao ^p   Verdel, B Marianne ^q   Lai, Mei Shu ^r   Kennedy, James ^s   Uchiyama, Shinichiro ^t   Yamaguchi, Takenori ^u   Ikeda, Yasuo ^v   Mrkobrada, Marko ^a   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF SYDNEY   (Australia)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j WAKE FOREST BAPTIST HEALTH   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF PERUGIA   (Italy)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^p NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^q UTRECHT UNIVERSITY   (Netherlands)

^r NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^u NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^v WASEDA UNIVERSITY   (Japan)

more..

Author keywords

cerebrovascular disorders; hemorrhage; meta analysis; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BRAIN HEMORRHAGE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANIMALS; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 81355160277     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.055269     Document Type: Article

References (50)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376: 1670-1681.
2. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559. (Pubitemid 44202151)
3. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
4. a Rordorf G, McDonald C. Spontaneous intracerebral hemorrhage: patho-genesis, clinical features, and diagnosis. In: Kasner SE, Wilterdink JL, eds. UpToDate, Version 18.2. Waltham, MA: UpToDate Inc; 2010.
5. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, revisions 9 and 10. Stroke. 2005; 36:1776-1781. (Pubitemid 41098778)
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. (Pubitemid 26120810)
7. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377-384. (Pubitemid 28438523)
8. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodi-alysis. N Engl J Med. 2009;360:1395-1407.
9. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-1239.
10. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Van-haecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
11. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368:1155-1163. (Pubitemid 44444932)
12. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemo-dialysis. N Engl J Med. 2005;353:238-248. (Pubitemid 41058323)
13. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361: 2024-2031. (Pubitemid 36695044)
14. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-1158 (Pubitemid 36398384)
15. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
16. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630 (Pubitemid 35379733)
17. MRC/BHF Heart Protection Study of cholesterol lowering with simva-statin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
18. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718 (Pubitemid 32259905)
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
20. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: 1615-1622. (Pubitemid 28248586)
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009. (Pubitemid 26338729)
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
24. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687. (Pubitemid 24320914)
25. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478-1485. (Pubitemid 44127567)
26. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002;18:220-228.
27. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR. Effects of atorvastatin on bone in postmeno-pausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab. 2007;92:4671-4677. (Pubitemid 350223443)
28. Kleemann A, Eckert S, von EA, Lepper W, Schernikau U, Gleichmann U, Hanrath P, Fleck E, Neiss A, Kerber S, Assmann G, Breithardt G. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA: the Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT). Eur Heart J. 1999;20:1393-1406. (Pubitemid 29435706)
29. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J. 2000;1:810-820.
30. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
31. Arima H, Tzourio C, Butcher K, Anderson C, Bousser MG, Lees KR, Reid JL, Omae T, Woodward M, MacMahon S, Chalmers J. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006;37:1497-1502. (Pubitemid 44305732)
32. Bushnell CD, Newby LK, Goldstein LB, Lin F, Yaffe K, Simon JA. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 2004;62:968-970. (Pubitemid 38435788)
33. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, Harrington RA, White HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37:1427-1431. (Pubitemid 44305721)
34. Capampangan DJ, Pearce LA, Asbury KL, Khoury JA, Benavente OR, Demaerschalk BM, Dodick DW, Ingall TT, Wieser JA, Aguilar MI. Lipid profile and statin use in ischemic stroke and intracerebral hemorrhage [abstract]. J Neurol Sci. 2009;285:S73.
35. Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke. 2010;41:1884-1890.
36. Chen PS, Li YH, Chang CL, Kao Yang YH. Early statin therapy improves clinical outcomes than delayed statin treatment in patients with acute ischemic stroke [abstract]. Circulation. 2010;122:A13376.
37. Douketis JD, Melo M, Bell CM, Mamdani MM. Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med. 2007;120:369.e9-369.e14.
38. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefevre T, Drouet E, Mulak G, Bataille V, Ferrieres J, Verstuyft C, Danchin N. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myo-cardial Infarction (FAST-MI) Registry. Circulation. 2011;123:474-482.
39. Fitz Maurice E, Wendell L, Snider R, Schwab K, Chanderraj R, Kinnecom Fitz Maurice E, Wendell L, Snider R, Schwab K, Chanderraj R, Kinnecom C, Nandigam K, Rost NS, Viswanathan A, Rosand J, Greenberg SM, Smith EE. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008;39:2151-2154.
40. Gregoire SM, Jager HR, Yousry TA, Kallis C, Brown MM, Werring DJ. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry. 2010;81:679-684.
41. Kennedy J, Quan H, Buchan AM, Ghali WA, Feasby TE. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke. 2005;36:2072-2076. (Pubitemid 41429222)
42. Sasaki J, Arakawa K, Iwashita M, Matsushita Y, Kono S. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study. Circ J. 2003;67:473-478. (Pubitemid 36702052)
43. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63:1868-1875. (Pubitemid 39532383)
44. Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther. 2011;89:89-96.
45. Verzini F, De RP, Parlani G, Giordano G, Caso V, Cieri E, Isernia G, Cao P. Effects of statins on early and late results of carotid stenting. J Vasc Surg. 2011;53:71-79.
46. Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Sza-flarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Sza-flarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke. 2004; 35:1360-1364.
47. Hackam D, Austin P, Huang A, Juurlink D, Mamdani M, Paterson J, Hachinski V, Li P, Kapral M. Statins and intracerebral hemorrhage: a retrospective cohort study [published online ahead of print September 12, 2011]. Arch Neurol. doi:10.1001/archneurol.2011.228.
48. Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T. The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: a randomized, double-blind, controlled trial. Cerebrovasc Dis. 2011;31:601-613.
49. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2007;38:3198-3204. (Pubitemid 350175737)
50. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-2370.